SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novacare (NOV) breaking out... -- Ignore unavailable to you. Want to Upgrade?

To: E. Graphs who wrote (155)10/28/1997 10:09:00 AM
From: Todd D. Wiener  Read Replies (1) | Respond to of 420
 
Analysis from Q4 to Q1:

Rehab revs increased 6%, NCES revs increased 19%. Those are good numbers.

Gross profit increased 4% for rehab, 46% for NCES. Cost of sales were higher for rehab in Q1 than in Q4. Overall gross profit increased 6%.

SG&A increased 13.7% for rehab (oops!), 46% for NCES (good cost control). Overall SG&A increased 15.2%.

EBITDA DECREASED 7.3% for rehab (damn than overhead!), increased 45% for NCES. Overall EBITDA DECREASED 4.4%.

Operating income DECREASED 8.6%.

Pretax income DECREASED 14.6%.

Net income DECREASED 15.7%.

I'm not impressed.

Todd



To: E. Graphs who wrote (155)10/30/1997 7:15:00 PM
From: Todd D. Wiener  Respond to of 420
 
I bought some November calls today (15 strike). NOV seems to be holding at its 200-day MA, although it's struggling a bit. The stock should breakout next week, because the downtrend and the moving average are currently converging, and I expect resolution. It will be interesting to see what effect NCES will have on NOV. It should help NOV go higher. I still believe in $18 by year-end. Based on the historical chart, now is the time to buy more NOV.

Todd


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News